Terms: = Lung cancer AND LDH AND Clinical Outcome
17 results:
1. Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors.
Zhao X; Wu X; Yu H; Wang H; Sun S; Hu Z; Liu C; Zhang J; Shao Y; Wang J
Front Immunol; 2022; 13():1003581. PubMed ID: 36341410
[TBL] [Abstract] [Full Text] [Related]
2. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell lung cancer: clinical outcome and Relevance of the lung Immune Prognostic Index.
Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
[TBL] [Abstract] [Full Text] [Related]
3. PIV and PILE Score at Baseline Predict clinical outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell lung cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract] [Full Text] [Related]
4. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract] [Full Text] [Related]
5. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Bersanelli M; Buti S; Giannarelli D; Leonetti A; Cortellini A; Russo GL; Signorelli D; Toschi L; Milella M; Pilotto S; Bria E; Proto C; Marinello A; Randon G; Rossi S; Vita E; Sartori G; D'Argento E; Qako E; Giaiacopi E; Ghilardi L; Bettini AC; Rapacchi E; Mazzoni F; Lavacchi D; Scotti V; Ciccone LP; De Tursi M; Di Marino P; Santini D; Russano M; Bordi P; Di Maio M; Audisio M; Filetti M; Giusti R; Berardi R; Fiordoliva I; Cerea G; Pizzutilo EG; Bearz A; De Carlo E; Cecere F; Renna D; Camisa R; Caruso G; Ficorella C; Banna GL; Cortinovis D; Brighenti M; Garassino MC; Tiseo M
Lung Cancer; 2020 Dec; 150():123-131. PubMed ID: 33130353
[TBL] [Abstract] [Full Text] [Related]
6. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract] [Full Text] [Related]
7. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang Z; Li Y; Yan X; Song Q; Wang G; Hu Y; Jiao S; Wang J
Cancer Med; 2019 Apr; 8(4):1467-1473. PubMed ID: 30848091
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.
Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
Acta Oncol; 2015 Jul; 54(7):961-70. PubMed ID: 25984930
[TBL] [Abstract] [Full Text] [Related]
9. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.
Buil-Bruna N; López-Picazo JM; Moreno-Jiménez M; Martín-Algarra S; Ribba B; Trocóniz IF
AAPS J; 2014 May; 16(3):609-19. PubMed ID: 24740245
[TBL] [Abstract] [Full Text] [Related]
10. The prognostic value of D-dimer in lung cancer.
İnal T; Anar C; Polat G; Ünsal İ; Halilçolar H
Clin Respir J; 2015 Jul; 9(3):305-13. PubMed ID: 24720709
[TBL] [Abstract] [Full Text] [Related]
11. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract] [Full Text] [Related]
12. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Koukourakis MI; Giatromanolaki A; Brekken RA; Sivridis E; Gatter KC; Harris AL; Sage EH
Cancer Res; 2003 Sep; 63(17):5376-80. PubMed ID: 14500371
[TBL] [Abstract] [Full Text] [Related]
13. lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours.
Zurita AJ; Diestra JE; Condom E; García Del Muro X; Scheffer GL; Scheper RJ; Pérez J; Germà-Lluch JR; Izquierdo MA
Br J Cancer; 2003 Mar; 88(6):879-86. PubMed ID: 12644825
[TBL] [Abstract] [Full Text] [Related]
14. The diagnostic value of pretreatment serum ldh in patients with limited disease small-cell lung carcinoma.
Stokkel MP; Van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Int J Biol Markers; 1997; 12(4):162-7. PubMed ID: 9582606
[TBL] [Abstract] [Full Text] [Related]
15. Pretreatment serum ldh as additional staging parameter in small-cell lung carcinoma.
Stokkel MP; van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Neth J Med; 1998 Feb; 52(2):65-70. PubMed ID: 9557528
[TBL] [Abstract] [Full Text] [Related]
16. Primary pulmonary lymphoma--clinical review from a single institution in Singapore.
Toh HC; Ang PT
Leuk Lymphoma; 1997 Sep; 27(1-2):153-63. PubMed ID: 9373207
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic factors: classification approaches in patients with lung cancer.
Stanisavljević D; Jovanović D; Marinković J; Milosavljević M
Stud Health Technol Inform; 1997; 43 Pt B():652-5. PubMed ID: 10179747
[TBL] [Abstract] [Full Text] [Related]
